Aung THAN

Featured Dataverses

In order to use this feature you must have at least one published dataverse.

Publish Dataverse

Are you sure you want to publish your dataverse? Once you do so it must remain published.

Publish Dataverse

This dataverse cannot be published because the dataverse it is in has not been published.

Delete Dataverse

Are you sure you want to delete your dataverse? You cannot undelete this dataverse.

1 to 10 of 43 Results

Dry powder microneedle-enabled transdermal anti-inflammatory therapy for obesity, diabetes, hyperlipidemia, and fatty liver Mar 11, 2024 - ZAN Ping Zan, Ping; Than, Aung; Leow, Melvin Khee Shing; Cai, Helen Xinyi; Wen, Hanqi; Zhang, Zheye; Chen, Peng, 2024, "Dry powder microneedle-enabled transdermal anti-inflammatory therapy for obesity, diabetes, hyperlipidemia, and fatty liver", https://doi.org/10.21979/N9/GCCTII, DR-NTU (Data), V1 Obese white adipose tissue (WAT) is characterized by hypoxia, oxidative stress, and inflammation, which are the key drivers of various deleterious diseases. Herein, we demonstrate a new strategy to directly induce ameliorative remodeling of obese subcutaneous WAT (sWAT). Manganes...
Figure1-v3.jpg Mar 11, 2024 - Dry powder microneedle-enabled transdermal anti-inflammatory therapy for obesity, diabetes, hyperlipidemia, and fatty liver JPEG Image - 3.9 MB - MD5: b463b08acfc110b088e8887096d3b73c
FigureS1-V2.jpg Mar 11, 2024 - Dry powder microneedle-enabled transdermal anti-inflammatory therapy for obesity, diabetes, hyperlipidemia, and fatty liver JPEG Image - 881.9 KB - MD5: e33c93290a91cda569908e9931f64bd7
FigureS6-whole blood-v2.jpg Mar 11, 2024 - Dry powder microneedle-enabled transdermal anti-inflammatory therapy for obesity, diabetes, hyperlipidemia, and fatty liver JPEG Image - 532.9 KB - MD5: c0d9ed30518739ce1c61dcb8b1beb70b
FigureS XPS copy.jpg Mar 11, 2024 - Dry powder microneedle-enabled transdermal anti-inflammatory therapy for obesity, diabetes, hyperlipidemia, and fatty liver JPEG Image - 505.4 KB - MD5: 9bab26996c322a2f5b5d9b98b2e83e74
mechanism scheme-1-6_1200 ppi.jpg Mar 11, 2024 - Dry powder microneedle-enabled transdermal anti-inflammatory therapy for obesity, diabetes, hyperlipidemia, and fatty liver JPEG Image - 7.8 MB - MD5: 646a42630fadd8a75c628307959f07bc
mechanism scheme-2-8.png Mar 11, 2024 - Dry powder microneedle-enabled transdermal anti-inflammatory therapy for obesity, diabetes, hyperlipidemia, and fatty liver PNG Image - 9.1 MB - MD5: f7bdc1140f61de6073fde7c0b209e59c
Lancing Drug Reservoirs into Subcutaneous Fat to Combat Obesity and Associated Metabolic Diseases Apr 5, 2021 Than, Aung, 2021, "Lancing Drug Reservoirs into Subcutaneous Fat to Combat Obesity and Associated Metabolic Diseases", https://doi.org/10.21979/N9/GXDXOJ, DR-NTU (Data), V1 Lancing Drug Reservoirs into Subcutaneous Fat to Combat Obesity and Associated Metabolic Diseases; Small 2020, 16, 2002872
A short summary for the Table of Content.docx Apr 5, 2021 - Lancing Drug Reservoirs into Subcutaneous Fat to Combat Obesity and Associated Metabolic Diseases MS Word - 320.5 KB - MD5: 5deb330c593721c153a0739cd7852390
Figure 1.jpg Apr 5, 2021 - Lancing Drug Reservoirs into Subcutaneous Fat to Combat Obesity and Associated Metabolic Diseases JPEG Image - 981.3 KB - MD5: 6e3110de52d2d2f3f11813cb86446a0b

Dry powder microneedle-enabled transdermal anti-inflammatory therapy for obesity, diabetes, hyperlipidemia, and fatty liver

Mar 11, 2024 - ZAN Ping

Zan, Ping; Than, Aung; Leow, Melvin Khee Shing; Cai, Helen Xinyi; Wen, Hanqi; Zhang, Zheye; Chen, Peng, 2024, "Dry powder microneedle-enabled transdermal anti-inflammatory therapy for obesity, diabetes, hyperlipidemia, and fatty liver", https://doi.org/10.21979/N9/GCCTII, DR-NTU (Data), V1

Obese white adipose tissue (WAT) is characterized by hypoxia, oxidative stress, and inflammation, which are the key drivers of various deleterious diseases. Herein, we demonstrate a new strategy to directly induce ameliorative remodeling of obese subcutaneous WAT (sWAT). Manganes...

Figure1-v3.jpg

Mar 11, 2024 - Dry powder microneedle-enabled transdermal anti-inflammatory therapy for obesity, diabetes, hyperlipidemia, and fatty liver

JPEG Image - 3.9 MB -

FigureS1-V2.jpg

Mar 11, 2024 - Dry powder microneedle-enabled transdermal anti-inflammatory therapy for obesity, diabetes, hyperlipidemia, and fatty liver

JPEG Image - 881.9 KB -

FigureS6-whole blood-v2.jpg

Mar 11, 2024 - Dry powder microneedle-enabled transdermal anti-inflammatory therapy for obesity, diabetes, hyperlipidemia, and fatty liver

JPEG Image - 532.9 KB -

FigureS XPS copy.jpg

Mar 11, 2024 - Dry powder microneedle-enabled transdermal anti-inflammatory therapy for obesity, diabetes, hyperlipidemia, and fatty liver

JPEG Image - 505.4 KB -

mechanism scheme-1-6_1200 ppi.jpg

Mar 11, 2024 - Dry powder microneedle-enabled transdermal anti-inflammatory therapy for obesity, diabetes, hyperlipidemia, and fatty liver

JPEG Image - 7.8 MB -

mechanism scheme-2-8.png

Mar 11, 2024 - Dry powder microneedle-enabled transdermal anti-inflammatory therapy for obesity, diabetes, hyperlipidemia, and fatty liver

PNG Image - 9.1 MB -

Lancing Drug Reservoirs into Subcutaneous Fat to Combat Obesity and Associated Metabolic Diseases

Apr 5, 2021

Than, Aung, 2021, "Lancing Drug Reservoirs into Subcutaneous Fat to Combat Obesity and Associated Metabolic Diseases", https://doi.org/10.21979/N9/GXDXOJ, DR-NTU (Data), V1

Lancing Drug Reservoirs into Subcutaneous Fat to Combat Obesity and Associated Metabolic Diseases; Small 2020, 16, 2002872

A short summary for the Table of Content.docx

Apr 5, 2021 - Lancing Drug Reservoirs into Subcutaneous Fat to Combat Obesity and Associated Metabolic Diseases

MS Word - 320.5 KB -

Figure 1.jpg

Apr 5, 2021 - Lancing Drug Reservoirs into Subcutaneous Fat to Combat Obesity and Associated Metabolic Diseases

JPEG Image - 981.3 KB -

Add Data

Share Dataverse

Link Dataverse

Reset Modifications